drugset

drugset / Trial / NCT01225471

Novel Peptide Vaccination for Patients With Advanced Prostate Cancer

NCT01225471 ↗

Phase 1/2 Unknown 30 enrolled Iwate Medical University Human Genome Center, Institute of Medical Science, University of Tokyo · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and clinical efficacy of novel peptide vaccination for advanced prostate cancer

Timeline

Start: 2009-06
Primary completion: 2011-05
Completion: 2012-05

Publications

Obara W, Sato F, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Mimata H, Sugai T, Nakamura Y, Fujioka T. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci. 2017 Jul;108(7):1452-1457. doi: 10.1111/cas.13278. Epub 2017 Jun 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CDCA1	Peptide	1 mg	Subcutaneous
Subject	CDCA1	Peptide	3 mg	Subcutaneous

Indications